Literature DB >> 9510862

HPLC determination of ketamine, norketamine, and dehydronorketamine in plasma with a high-purity reversed-phase sorbent.

S Bolze1, R Boulieu.   

Abstract

We developed an isocratic, selective, and very sensitive HPLC method for the determination of ketamine and its two main metabolites in plasma. The compounds were extracted from plasma by a liquid-liquid extraction with a dichloromethane:ethyl acetate mixture followed by an acidic back-extraction. Separation was achieved on a new stationary phase, Purospher RP-18 endcapped, with a mobile phase containing acetonitrile:0.03 mol/L phosphate buffer (23:77 by vol) adjusted to pH 7.2. Because of the high column efficiency and the significant improvement of peak symmetry, the quantification limit could be down to 5 micrograms/L for ketamine and norketamine (NK). The intraday and interday CVs ranged from 1.7% to 5.8% and 3.1% to 10.2% for all compounds respectively. The method is sensitive enough for monitoring ketamine, NK, and dehydroketamine in plasma during pharmacokinetic studies after an intravenous bolus of a low dose of ketamine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9510862

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  15 in total

1.  Kinetics of ketamine plasma and urine metabolite levels following intravenous administration in the dog.

Authors:  P Roncada; A Zaghini; C Riciputi; N Romagnoli; A Spadari
Journal:  Vet Res Commun       Date:  2003-09       Impact factor: 2.459

2.  A parallel chiral-achiral liquid chromatographic method for the determination of the stereoisomers of ketamine and ketamine metabolites in the plasma and urine of patients with complex regional pain syndrome.

Authors:  Ruin Moaddel; Swarajya Lakshmi Vattem Venkata; Mary J Tanga; James E Bupp; Carol E Green; Lalitha Iyer; Anna Furimsky; Michael E Goldberg; Marc C Torjman; Irving W Wainer
Journal:  Talanta       Date:  2010-08-13       Impact factor: 6.057

3.  Pharmacokinetic-pharmacodynamic modelling of ketamine in six neurotraumatised intensive care patients.

Authors:  Youssef Hijazi; Carole Bodonian; François Salord; Françoise Bressolle; Roselyne Boulieu
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

4.  Influence of prior determination of baseline minimum alveolar concentration (MAC) of isoflurane on the effect of ketamine on MAC in dogs.

Authors:  Giacomo Gianotti; Alexander Valverde; Ron Johnson; Melissa Sinclair; Thomas Gibson; Doris H Dyson
Journal:  Can J Vet Res       Date:  2014-07       Impact factor: 1.310

Review 5.  Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Lace M Riggs; Jaclyn N Highland; Polymnia Georgiou; Edna F R Pereira; Edson X Albuquerque; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

6.  Stereoselective and regiospecific hydroxylation of ketamine and norketamine.

Authors:  Zeruesenay Desta; Ruin Moaddel; Evan T Ogburn; Cong Xu; Anuradha Ramamoorthy; Swarajya Lakshmi Vattem Venkata; Mitesh Sanghvi; Michael E Goldberg; Marc C Torjman; Irving W Wainer
Journal:  Xenobiotica       Date:  2012-05-21       Impact factor: 1.908

7.  Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression.

Authors:  Xiaochen Zhao; Swarajya Lakshmi Vattem Venkata; Ruin Moaddel; Dave A Luckenbaugh; Nancy E Brutsche; Lobna Ibrahim; Carlos A Zarate; Donald E Mager; Irving W Wainer
Journal:  Br J Clin Pharmacol       Date:  2012-08       Impact factor: 4.335

8.  Ketamine Pharmacokinetics and Pharmacodynamics Are Altered by P-Glycoprotein and Breast Cancer Resistance Protein Efflux Transporters in Mice.

Authors:  Samit Ganguly; John C Panetta; Jessica K Roberts; Erin G Schuetz
Journal:  Drug Metab Dispos       Date:  2018-04-19       Impact factor: 3.922

9.  Use of human microsomes and deuterated substrates: an alternative approach for the identification of novel metabolites of ketamine by mass spectrometry.

Authors:  Sophie C Turfus; Mark C Parkin; David A Cowan; John M Halket; Norman W Smith; Robin A Braithwaite; Simon P Elliot; Glyn B Steventon; Andrew T Kicman
Journal:  Drug Metab Dispos       Date:  2009-05-15       Impact factor: 3.922

Review 10.  Ketamine : from medicine to misuse.

Authors:  Kim Wolff; Adam R Winstock
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.